2. Signaling Pathways
  3. GPCR/G Protein
    Neuronal Signaling
  4. Dopamine Receptor
  5. Dopamine Receptor Isoform
  6. Dopamine Receptor Inhibitor

Dopamine Receptor Inhibitor

Dopamine Receptor Inhibitors (87):

Cat. No. Product Name Effect Purity
  • HY-16771B
    Valbenazine dihydrochloride
    		Inhibitor
    Valbenazine (NBI-98854) dihydrochloride is a VMAT2 inhibitor, used to treat tardive dyskinesia. Valbenazine dihydrochloride demonstrates potential benefit in alleviating symptoms associated with movement disorders resulting from chronic dopamine receptor blocking medications. Valbenazine dihydrochloride has been supported by evidence from preclinical models examining its role in the genetic factors linked to tardive dyskinesia.
  • HY-B0520AR
    Benztropine (mesylate) (Standard)
    		Inhibitor
    Benztropine (mesylate) (Standard) is the analytical standard of Benztropine (mesylate). This product is intended for research and analytical applications. Benztropine mesylate (Benzatropine mesylate) is an orally active centrally acting anticholinergic agent that can be used for Parkinson's disease research. Benztropine mesylate is an anti-histamine agent and a dopamine re-uptake inhibitor. Benztropine mesylate is also a human D2 dopamine receptor allosteric antagonist. Benztropine mesylate also has anti-CSCs (cancer stem cells) effects.
  • HY-12987S2
    Pimozide-d4-1
    		Inhibitor
    Pimozide-d4-1 is the deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5[1][2][3][4].
  • HY-160997
    Prosulpride
    		Inhibitor
    Prosulpride (GRI 1665), a neuroleptics, can block selectively dopaminergic receptor.
  • HY-129682
    LY125180
    		Inhibitor
    LY125180 is a serotonin uptake inhibitor. LY125180 competitively inhibits the uptake of serotonin and norepinephrine by cortical synaptosomes and of dopamine by striatal synaptosomes, with Ki values of 0.06 μM, 2.2 μM and 2.5 μM respectively.
  • HY-124357
    Seproxetine hydrochloride
    		Inhibitor
    Seproxetine (S-Norfluoxetine) hydrochloride is a selective serotonin reuptake inhibitor (SSRI) that enhances serotonin levels in the brain by specifically inhibiting the serotonin uptake carrier. Seproxetine hydrochloride exhibits strong charge transfer interactions with π-electron acceptors, forming stable complexes that enhance its binding affinity to multiple receptors, including serotonin and dopamine receptors. Seproxetine hydrochloride demonstrates improved biological activity when interacting with charge transfer complexes, leading to increased stability and efficacy in therapeutic applications.
  • HY-B0901R
    Bromperidol (Standard)
    		Inhibitor
    Bromperidol (Standard) is the analytical standard of Bromperidol. This product is intended for research and analytical applications. Bromperidol (R-11333) possesses antipsychotic activity, with a high affinity for central dopamine receptors D2. Bromperidol can kill Mycobacteria in a synergistic manner with Spectinomycin.
  • HY-106079
    Fezolamine
    		Inhibitor
    Fezolamine is an orally active non-tricyclic compound , and shows antidepressant activity.
  • HY-127086
    Dicarbine
    		Inhibitor
    Dicarbine blocks dopamine receptors in various brain parts and prevents the depression of the conditioned defence reflexes caused by stimulation of the mesencephalic portion of the reticular formation. Dicarbine could be used in the schizophrenia and alcoholic psychosis studies.
  • HY-B0532AR
    Trifluoperazine (dihydrochloride) (Standard)
    		Inhibitor
    Trifluoperazine (dihydrochloride) (Standard) is the analytical standard of Trifluoperazine (dihydrochloride). This product is intended for research and analytical applications. Trifluoperazine dihydrochloride, an antipsychotic agent, acts by blocking central dopamine receptors. Trifluoperazine dihydrochloride is a potent α1-adrenergic receptor antagonist. Trifluoperazine dihydrochloride is a potent NUPR1 inhibitor exerting anticancer activity. Trifluoperazine dihydrochloride is a calmodulin inhibitor, and also inhibits P-glycoprotein. Trifluoperazine dihydrochloride can be used for the research of schizophrenia. Trifluoperazine dihydrochloride acts as a reversible inhibitor of influenza virus morphogenesis.
  • HY-N5140R
    Bacopaside X (Standard)
    		Inhibitor
    Bacopaside X (Standard) is the analytical standard of Bacopaside X. This product is intended for research and analytical applications. Bacopaside X is found in Bacopa monnieri, and shows a binding affinity toward the D1 receptor.
  • HY-A0081R
    Fluphenazine (dihydrochloride) (Standard)
    		Inhibitor
    Fluphenazine (dihydrochloride) (Standard) is the analytical standard of Fluphenazine (dihydrochloride). This product is intended for research and analytical applications. Fluphenazine dihydrochloride is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine dihydrochloride blocks neuronal voltage-gated sodium channels. Fluphenazine dihydrochloride acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine dihydrochloride can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine dihydrochloride can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2.
  • HY-127086A
    Dicarbine dihydrochloride
    		Inhibitor
    Dicarbine dihydrochloride blocks dopamine receptors in various brain parts and prevents the depression of the conditioned defence reflexes caused by stimulation of the mesencephalic portion of the reticular formation. Dicarbine dihydrochloride could be used in the schizophrenia and alcoholic psychosis studies.
  • HY-A0163A
    Clopenthixol
    		Inhibitor
    Clopenthixol is a thiaquinoline compound with inhibitory effects similar to those of phenothiazine antipsychotics. Clopenthixol is an antagonist of D1 and D2 dopamine receptors. Clopenthixol is mainly used to suppress schizophrenia and other mental disorders.
  • HY-B0532S
    Trifluoperazine-d8
    		Inhibitor
    Trifluoperazine-d8 is a deuterium labeled Trifluoperazine. Trifluoperazine is an antipsychotic phenothiazine agent and a selective α1-adrenergic receptor antagonist. Trifluoperazine is also a potent dopamine D2 receptor inhibitor [1][2].
  • HY-113468AS1
    3-O-Methyldopa-d3 hydrate
    		Inhibitor
    3-O-Methyldopa-d3 (hydrate) is the deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine[1].
  • HY-B1196R
    Tiapride (hydrochloride) (Standard)
    		Inhibitor
    Tiapride (hydrochloride) (Standard) is the analytical standard of Tiapride (hydrochloride). This product is intended for research and analytical applications. Tiapride hydrochloride is a selective and orally active D2 and D3 dopamine receptors antagonist with IC50 values of 110-320 nM and 180 nM, respectively. Tiapride hydrochloride shows anti-dyskinetic activity and anxiolytic activity. Tiapride hydrochloride is a neuroleptic agent.
  • HY-W401531S1
    (R)-3-O-Methyldopa-d3 hydrochloride
    		Inhibitor
    (R)-3-O-Methyldopa-d3 (hydrochloride) is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine[1][2].
  • HY-A0081S
    Fluphenazine-d8 dihydrochloride
    		Inhibitor 99.81%
    Fluphenazine-d8 (dihydrochloride) is the deuterium labeled Fluphenazine dihydrochloride. Fluphenazine dihydrochloride is a phenothiazine-class D1DR and D2DR inhibitor; used to deliver Fluphenazine to biological systems in studies probing the effects and metabolic fates of this commonly used dopamine antagonist.
  • HY-116450
    TISCH
    		Inhibitor
    TISCH is a potent and selective iodinated ligand with high affinity and selectivity for CNS D1 dopamine receptors. TISCH showed a Kd value of 0.205 nM in rat striatal tissue, indicating its effectiveness in biological activity. TISCH is able to easily cross the blood-brain barrier and show distribution in specific areas with D1 receptor density. TISCH is considered to be useful as a pharmacological tool for characterizing D1 dopamine receptors. When labeled with I-123, TISCH has the potential to be used as an in vivo imaging agent for CNS D1 dopamine receptors.